International journal of hematologic oncology · 2022
Turkey real-life data: demographic features, treatment results and effects of comorbidities in chronic myeloid leukemia.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Saydam Guray, Unal Ali, Haznedaroglu Ibrahim Celalettin, Hacihanifioglu Abdullah, Mehtap Ozgur, Kurtoglu Erdal, Gocer Mesut, Turgut Mehmet, Kelkitli Engin, Atay Memis Hilmi, Guler Nil, Koluman Basak Unver, Sonmez Mehmet, Erkut Nergiz, Kaya Emin, Kuku Irfan, Erkurt Mehmet Ali, Ozet Gulsum, Ceran Funda, Sahin Fahri, Soyer Nur, Nalcaci Meliha, Yilmaz Mehmet, Bozkurt Sirac, Aver Birkan, Ozdengulsun Begum, Ozbilgili Egemen, Ilhan Osman
Аннотация
AIM: This study aimed to identify patient characteristics, treatment patterns and outcomes and to evaluate the effects of presence of comorbidities at diagnosis in chronic phase (CP)-chronic myeloid leukemia (CML) patients in Turkey.
MATERIALS & METHODS: Hospital records between 2005 and 2018 were retrospectively reviewed.
RESULTS: Of 861 CP-CML patients included, 31% had at least one comorbidity at diagnosis. Sex, cardiovascular disease status at diagnosis and molecular (at least major) and cytogenetic (partial and complete) responses were the independent predictors of survival.
CONCLUSION: The response rates of CP-CML patients to the tyrosine kinase inhibitors were satisfactory. In addition to tolerability and side effect profiles of drugs, comorbidity status of patients should also be considered in treatment choice in CML patients.
MATERIALS & METHODS: Hospital records between 2005 and 2018 were retrospectively reviewed.
RESULTS: Of 861 CP-CML patients included, 31% had at least one comorbidity at diagnosis. Sex, cardiovascular disease status at diagnosis and molecular (at least major) and cytogenetic (partial and complete) responses were the independent predictors of survival.
CONCLUSION: The response rates of CP-CML patients to the tyrosine kinase inhibitors were satisfactory. In addition to tolerability and side effect profiles of drugs, comorbidity status of patients should also be considered in treatment choice in CML patients.